Todd R. Golub, MD, Margaret A. Shipp, MD, and Bruce M. Spiegelman, PhD, of Dana-Farber Cancer Institute, have been elected to the Institute of Medicine (IOM), a nongovernmental organization that advises the nation on issues related to biomedical science, medicine, and health.
Election to the IOM is considered one of the highest honors in the fields of health and medicine, recognizing individuals who have demonstrated outstanding professional achievement and commitment to service.
Golub is the Charles A. Dana Investigator of Human Cancer Genetics at Dana-Farber, professor of pediatrics at Harvard Medical School, and Founding Director of the Cancer Program at the Broad Institute of Harvard and MIT. He is also an Investigator of the Howard Hughes Medical Institute.
Golub's research focuses on using genomic approaches to study cancer biology and cancer medicine. His laboratory has developed new approaches to classifying cancers based on their genomic aberrations, and has pioneered new approaches to cancer drug discovery.
Shipp, who specializes in hematologic oncology, is the chief of the Division of Hematological Neoplasia at Dana-Farber and director of the Lymphoma Program at Dana-Farber/Harvard Cancer Center. She is also a Professor of Medicine at Harvard Medical School.
Shipp's research focuses on the genetic abnormalities and signaling pathways responsible for aggressive B-cell lymphomas, including the most common lymphoid malignancy, diffuse large B-cell lymphoma, and Hodgkin lymphoma. The goal of the research is to improve treatment for these blood cancers.
Spiegelman is a cancer biologist and director of the Center for Energy Metabolism and Chronic Disease at Dana-Farber, and the Stanley J. Korsmeyer Professor of Cell Biology and Medicine at Harvard Medical School.
His research has identified key molecules that help regulate the body's energy metabolism and are implicated in processes leading to obesity, diabetes, and other disorders. Some of his recent findings about the development of energy-burning brown and beige fat cells are being developed as potential treatments for metabolic disorders including obesity and cancer cachexia.
The IOM announced 70 new members and 10 foreign associates during its 44th annual meeting earlier this week.
"It is with great enthusiasm that we welcome our esteemed colleagues to the Institute of Medicine," said IOM President Victor J. Dzau. "These leaders' tremendous achievements have contributed significantly to advancing health and medicine. The expertise and knowledge they bring to the IOM will encourage and enhance its success."